Everything You Need To Know About: GLP-1 Medications & Eating Disorders
Expert nutrition support for individuals using GLP-1 medications — with a history of disordered eating or an active eating disorder diagnosis.
GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® have changed the landscape of diabetes and weight management — but for anyone navigating a history of disordered eating, starting one of these medications raises questions that go well beyond the prescription. At Laura Cipullo Whole Nutrition, we specialize in exactly this intersection: providing evidence-based nutritional support for individuals using GLP-1 medications who also carry a history of — or active diagnosis of — an eating disorder. Whether you're newly prescribed, already mid-treatment, or simply trying to understand your options, we're here to help you move forward safely.
Table of Contents
- Introduction
- What are GLP-1 medications, and how do they work?
- Who is typically prescribed a GLP-1 medication?
- What is the connection between GLP-1 medications and eating disorders?
- Can GLP-1 medications help with binge eating disorder?
- What are the risks for people with restrictive eating disorders (anorexia, ARFID)?
- What nutritional complications can occur on a GLP-1 medication?
- Should I tell my prescriber about my eating disorder history before starting a GLP-1?
- How does a registered dietitian specializing in eating disorders support GLP-1 users?
- Can I take a GLP-1 medication if I am in eating disorder recovery?
- How do I find a dietitian experienced with both GLP-1 medications and eating disorders?
- What should I bring to my first appointment?
- Frequently Asked Questions
Introduction
The rise of GLP-1 receptor agonists — medications like Ozempic® (semaglutide), Wegovy®, Mounjaro® (tirzepatide), and Victoza® (liraglutide) — has transformed how clinicians approach type 2 diabetes and weight management. But for the millions of people who live with a history of disordered eating, these medications raise questions that go far beyond the scale.
GLP-1 medications work by mimicking a gut hormone that regulates appetite, slows digestion, and stimulates insulin production. Those effects — less hunger, feeling full sooner, reduced food cravings — may sound straightforwardly positive. But for someone with a history of anorexia, binge eating disorder, bulimia, or other eating disorders, appetite suppression is not a neutral experience. It can reinforce restriction. It can trigger old behaviors. And it can happen quietly, in ways that neither the patient nor their prescribing physician is watching for.
At Laura Cipullo Whole Nutrition, we work with clients navigating exactly this intersection — because eating disorders and metabolic health conditions like type 2 diabetes, PCOS, and insulin resistance frequently co-occur. Our role is to help you understand what GLP-1 medications may mean for your relationship with food, your body, and your recovery — and to ensure that if you are prescribed one, you have the expert nutritional support to use it safely.
What are GLP-1 medications, and how do they work?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after eating. GLP-1 receptor agonists are a class of medications that mimic this hormone, producing several effects simultaneously: they stimulate insulin secretion when blood sugar is elevated, suppress glucagon (which would otherwise raise blood sugar), slow the rate at which food leaves the stomach, and act on appetite centers in the brain to reduce hunger and food cravings.
Originally developed and FDA-approved for type 2 diabetes management, several GLP-1 medications have since received approvals for chronic weight management as well. The most commonly prescribed include:
- Ozempic® / Wegovy® (semaglutide) — weekly injection
- Mounjaro® / Zepbound® (tirzepatide) — weekly injection; also a GIP agonist
- Victoza® / Saxenda® (liraglutide) — daily injection
- Rybelsus® (oral semaglutide) — daily pill
These medications are not a cure for any condition. They work best as part of a comprehensive approach that includes medical supervision, nutritional support, and behavioral health care — particularly for individuals with complex histories around food and eating.
Learn more: Laura Cipullo's Endocrine Health (PCOS & Diabetes) services →
Who is typically prescribed a GLP-1 medication?
GLP-1 medications are FDA-approved for adults with type 2 diabetes and, in higher-dose formulations, for chronic weight management in individuals with a BMI of 30 or above (or 27+ with a weight-related condition). They are increasingly prescribed off-label, and their availability has expanded rapidly — with approximately one in eight U.S. adults having used a GLP-1 medication as of recent estimates.
This broad prescribing landscape means that many individuals receiving a GLP-1 prescription have not been screened for a history of disordered eating — a gap that eating disorder specialists and researchers are urgently calling attention to.
What is the connection between GLP-1 medications and eating disorders?
The relationship between GLP-1 medications and eating disorders is complex, bidirectional, and still being actively researched. Here is what current evidence suggests:
GLP-1 medications may benefit some eating disorder presentations:
Research published in Obesity Reviews (2025) found that binge eating episodes and prevalence reduced following liraglutide and semaglutide use, and binge eating scores improved with liraglutide compared to placebo. A separate 2025 narrative review published in Nutrients found that GLP-1 receptor agonists reduce hunger and binge-eating frequency, suggesting possible benefits for binge-type eating disorders.
GLP-1 medications may pose significant risks for others:
The same research indicates that for individuals with restrictive eating disorders — particularly anorexia nervosa — the appetite suppression produced by GLP-1 medications may reinforce rigid dietary control and perfectionistic traits around eating, potentially deepening restriction rather than improving it.
A 2025 analysis of de-identified health records found that patients with any pre-existing mental health condition had more than double the risk of developing a new eating disorder diagnosis within two years of starting a GLP-1 medication, compared to those without mental health history. Cumulative incidence of new eating disorder diagnoses — predominantly anorexia nervosa — was 1.275% among GLP-1 users.
Psychiatric adverse effects including anxiety, depression, and disordered eating behaviors have also been documented in GLP-1 clinical data. Case reports describe extreme appetite suppression, pathological dietary restriction, and psychological complications, sometimes requiring discontinuation.
The bottom line: GLP-1 medications are not inherently dangerous for people with eating disorder histories — but they are not neutral either. The outcome depends heavily on which eating disorder is involved, where someone is in recovery, what monitoring and support is in place, and whether the care team is equipped to recognize warning signs.
Relevant research:
- Krug et al. (2025). Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes. Nutrients. Read study →
- Jebeile et al. (2025). GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. Obesity Reviews. Read study →
Can GLP-1 medications help with binge eating disorder?
This is one of the most clinically promising — and carefully watched — areas of GLP-1 research. Binge eating disorder (BED) is characterized by recurrent episodes of eating large amounts of food in a short period, accompanied by a sense of loss of control. GLP-1 medications may interrupt this cycle through two mechanisms: reducing appetite and food cravings, and modulating the brain's dopamine-driven reward pathways that are implicated in compulsive eating.
A 2025 narrative review in the International Journal of Molecular Sciences examined GLP-1 receptor agonists' therapeutic potential for BED, finding that GLP-1 receptors are expressed in hypothalamic nuclei regulating energy homeostasis and mesolimbic circuits controlling food reward — suggesting a genuine biological mechanism for symptom reduction.
However, this research comes with important caveats:
- Current studies remain small-scale with significant methodological limitations
- No GLP-1 medication is currently FDA-approved specifically for treating binge eating disorder
- The suppression of appetite that may reduce bingeing in some individuals could paradoxically reinforce restriction in others — especially if binge-purge cycles are present
If you have binge eating disorder and are considering a GLP-1 medication, working with a registered dietitian who specializes in eating disorders before and during treatment is essential — not optional. A dietitian can help you monitor your eating patterns, nutritional intake, and emotional relationship with food throughout the course of treatment.
What are the risks for people with restrictive eating disorders (anorexia, ARFID)?
For individuals with anorexia nervosa, orthorexia, ARFID (Avoidant/Restrictive Food Intake Disorder), or other restrictive presentations, GLP-1 medications carry distinct and serious risks:
Reinforcement of restriction: GLP-1-induced appetite suppression can feel like "succeeding" at eating less — which, for someone with a restrictive eating disorder, can activate the disorder's core cognitive patterns and behaviors, even if the person is in recovery.
Accelerated nutritional depletion: Research published in 2025 found that some individuals on GLP-1 therapy consume fewer than 800 calories per day in early treatment phases. For someone already restricting, this compounds existing nutritional deficits. Prolonged energy and protein deficits increase the risk of sarcopenia (muscle loss), metabolic dysfunction, and micronutrient deficiencies including vitamin D, B12, iron, calcium, and magnesium.
Lack of screening: Individuals with restrictive eating disorders are not always forthcoming about their history, and prescribers are not always trained to screen for it. This creates a significant care gap.
GLP-1 medications are generally contraindicated in active anorexia nervosa and require extreme caution and specialized monitoring in anyone with a restrictive eating disorder history. If you have been prescribed a GLP-1 medication and have this history, please discuss it with both your prescriber and a qualified eating disorder dietitian before beginning or continuing the medication.
What nutritional complications can occur on a GLP-1 medication?
Even for individuals without eating disorder histories, GLP-1 medications can create nutritional challenges that require dietary attention. A 2025 narrative review found that people on GLP-1 therapy frequently fall short on key nutrients including fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E — while sometimes exceeding limits for total and saturated fat.
Common nutritional concerns on GLP-1 therapy include:
- Severe caloric restriction — nausea and appetite suppression can make it difficult to consume enough calories to sustain lean body mass
- Protein deficiency — inadequate protein accelerates muscle loss, which GLP-1 medications are already associated with
- Micronutrient gaps — reduced food volume means less dietary diversity and lower intake of essential vitamins and minerals
- Dehydration — GLP-1 medications frequently cause nausea and vomiting, increasing the risk of dehydration and electrolyte imbalance
- Disordered meal patterns — skipping meals due to reduced hunger can destabilize blood sugar and contribute to irregular eating behaviors
A registered dietitian can assess your baseline nutritional status, help you structure eating patterns that ensure adequate intake within your reduced appetite, recommend targeted supplementation where needed, and monitor for signs of nutritional depletion over time.
Related resource: Endocrine Health & Diabetes Nutrition at Laura Cipullo →
Should I tell my prescriber about my eating disorder history before starting a GLP-1?
Yes — absolutely and always.
Eating disorder history is clinically relevant information for any prescriber considering a GLP-1 medication. It affects risk assessment, monitoring requirements, and whether additional support (such as a dietitian or therapist) should be in place before the medication begins.
Many people feel hesitant to disclose eating disorder history out of fear of being judged, dismissed, or having the medication withheld. But disclosure is the single most protective step you can take. If you are unsure how to bring it up, a registered dietitian can help you prepare for that conversation — and can coordinate with your medical team as part of a multidisciplinary approach.
At Laura Cipullo Whole Nutrition, we believe the best care requires a multidisciplinary approach. We work collaboratively with prescribing physicians, endocrinologists, therapists, and other members of your care team to ensure your nutrition plan and your medical plan are aligned.
How does a registered dietitian specializing in eating disorders support GLP-1 users?
Working with a dietitian who understands both GLP-1 pharmacology and eating disorder recovery is meaningfully different from working with a general dietitian. Here is what that specialized support looks like in practice:
Before you begin a GLP-1 medication, a dietitian can evaluate your current eating patterns, nutritional status, and eating disorder history to identify potential risks and establish a baseline.
As GLP-1 appetite suppression sets in, your dietitian tracks changes in your meal structure, food variety, and caloric intake — watching for early signs of problematic restriction or other disordered behaviors.
With reduced hunger as a constant factor, your dietitian helps you meet protein, micronutrient, and caloric needs through intentional, structured eating — not hunger cues alone.
A dietitian with eating disorder training understands the psychological dimensions of food, body image, and appetite regulation. They can help you interpret your reduced hunger without slipping into restriction-rewarding patterns.
Your dietitian communicates with your prescriber, endocrinologist, and therapist so that your nutritional status and eating behaviors are part of the clinical picture — not evaluated in isolation.
Where dietary intake alone cannot meet nutritional needs, your dietitian recommends evidence-based supplementation and monitors your response.
Can I take a GLP-1 medication if I am in eating disorder recovery?
This depends on your specific situation, which eating disorder you are recovering from, how stable your recovery is, and whether adequate support is in place. There is no universal answer.
For some individuals in stable recovery from binge eating disorder, a GLP-1 medication — with appropriate monitoring — may be both safe and beneficial. For someone in early anorexia recovery, the risks of introducing appetite suppression may substantially outweigh any benefits.
This is precisely the type of question that a registered dietitian specializing in eating disorders is positioned to help you think through in collaboration with your prescribing physician. The goal is not to categorically prevent access to a medication that might genuinely help — it is to ensure that any decision is made with full clinical awareness of your eating disorder history, and with a support structure in place to catch problems early.
How do I find a dietitian experienced with both GLP-1 medications and eating disorders?
The intersection of eating disorders and GLP-1 pharmacotherapy is genuinely specialized — not every dietitian has training in both. When searching, look for:
- CEDRD (Certified Eating Disorder Registered Dietitian) — the highest credential in eating disorder nutrition care, issued by the International Association of Eating Disorders Professionals (IAEDP)
- RD or RDN — registered with the Commission on Dietetic Registration
- Experience with endocrine conditions — diabetes, PCOS, insulin resistance, as these frequently co-occur with eating disorders
- Familiarity with GLP-1 medications — the nutritional implications of GLP-1 therapy are still emerging, and not all dietitians have kept current
Laura Cipullo, MS, RD, CEDRD-S, CDN, holds the Certified Eating Disorder Registered Dietitian-Supervisor credential and has over 25 years of clinical experience at the intersection of eating disorders and metabolic health. Her team at Laura Cipullo Whole Nutrition accepts both in-person and virtual telehealth appointments — meaning you can access specialized care regardless of your location.
What should I bring to my first appointment?
Coming prepared to your first consultation helps us understand your full picture as quickly as possible. Consider bringing:
- A list of your current medications, including your GLP-1 medication, dosage, and how long you have been taking it
- Any recent lab work (blood glucose, HbA1c, lipid panel, vitamin/mineral panels)
- A general sense of your current eating patterns (a food diary from the past few days is helpful, but not required)
- Your eating disorder treatment history, including past diagnoses, treatment programs, and current therapist or treatment team members
- Any questions you have — there are no wrong ones
If you feel uncertain about disclosing your eating disorder history, please know that our team works with these complex presentations every day. Our approach is nonjudgmental, evidence-based, and grounded in a whole-person philosophy of care.
Frequently Asked Questions about GLP-1's & Eating Disorders
Safety depends on your individual history, specific diagnosis, recovery stability, and the support structure in place. It is not categorically safe or unsafe — which is why specialized assessment by a registered dietitian and your prescribing physician is essential before beginning.
Research suggests they can, particularly for individuals with restrictive eating disorders. The appetite suppression these medications produce may reinforce restriction in vulnerable individuals. Close monitoring by an eating disorder-trained dietitian significantly reduces this risk.
A Certified Eating Disorder Registered Dietitian (CEDRD) has completed specialized post-graduate training in eating disorder treatment and passed a certification examination through IAEDP. This credential indicates a higher level of expertise in the complex psychological and nutritional dimensions of eating disorder care.
Coverage varies by plan. We recommend contacting your insurance provider to confirm coverage for medical nutrition therapy (MNT). Our fees page provides additional detail. View fees →
Yes. We welcome referrals from prescribing physicians, endocrinologists, therapists, and other clinicians. You can also visit our Eating Disorder Workshop for Clinicians page → for professional training resources.
